Physicians who choose to partner with DaVita have direct access to a network of leading clinical experts in our discipline. Together, DaVita's entire clinical team — including the Office of the Chief Medical Officer (OCMO) in the United States (U.S.), our European clinical leadership team and all of our physician partners — identifies, shapes and drives the patient programs that are adapted locally and implemented in Portugal. We listen to our physician teammates because they know better than anyone what is best for their patients.
DaVita established OCMO in the U.S. as a group of experienced nephrologists dedicated to working with the business leadership to provide value for patients, deliver high-quality outcomes and be responsible stewards of resources while always ensuring the highest level of care.
ALLEN R. NISSENSON, MD, FACP | CHIEF MEDICAL OFFICER, DAVITA
A prolific author and renowned authority on kidney disease, Allen R. Nissenson, MD, FACP, is emeritus professor of medicine at the David Geffen School of Medicine at UCLA, where he has served as associated dean and director of the dialysis program. Dr. Nissenson is a former president of the Renal Physicians Association (RPA) and, prior to that, served on the RPA board of directors as a special advisor to the president. Dr. Nissenson has also served as president of the Southern California ESRD Network. Read Allen's Blog »
STEFAN H JACOBSON, MD, PhD | CEO AND PROFESSOR OF NEPHROLOGY, DANDERYD UNIVERSITY HOSPITAL
Professor Jacobson, in addition to being CEO and professor of nephrology at Danderyd University Hospital, is the associate editor of the Scandinavian Journal of Urology. Prior to Danderyd University Hospital, Professor Jacobson served first as the Head of the medical division and then as the director of the nephrology Department at Karolinksa Hospital and Korolinksa Institute. He has written or contributed to over 150 publications in journals around the world, and focuses his research on inflammation and cardio-vascular disease, leukocyte function, transmigration of leukocytes, IgA nephropathy and cardio renal syndrome. Professor Jacobson also serves on several international study and steering committees, with a focus on the randomized controlled study of the effects of hemodialysis (membrane permeability outcome study, MPO study), the practice pattern in hemodialysis (dialysis outcome practice pattern study, DOPPS), and the effects of cinacalcet (ECHO).
MACIEJ DROŻDŻ, MD, PhD, CHIEF MEDICAL DIRECTOR, POLAND
As Chief Medical Director for DaVita’s operations in Europe and the Middle East, Dr. Drozdz worked for more than 20 years at University Hospital in Kraków and served as the head of the dialysis unit in the department of nephrology.
He has written or contributed to nearly 40 journal publications, including six chapters in polish nephrological textbooks. His research focuses on cardiovascular challenges for dialysis patients and intradialytic anticoagulation. As both principal and co-investigator he took part in phase II, III and IV clinical trials.
ANDRÉ WEIGERT, MD, PhD; MEDICAL COORDINATOR OF DAVITA IN PORTUGAL
Born in Rio de Janeiro, Brazil. MD in 1984 (with Honors) and PhD in Pharmacology and Medicine (with Honors) in 1999 at the University of Lisbon, Portugal. Post-Graduate Training: Hospital S. Maria (85-86) and Hospital Santa Cruz (86-87); Residence in Internal Medicine through the Clinical Investigator pathway, including 18 months of Research on endothelial function at the Center for Experimental Therapeutics, Baylor College of Medicine (BCM; mentor: Prof Paul Vanhoutte) from 1988-91. Chief Medical Resident at the VAMC of Houston/BCM in 1992 (Chief of Medicine: Prof Andrew Schafer). Fellowship in Nephrology at the University of Colorado, in Denver (92-95; mentor: Prof Robert W. Schrier). Obtained the American Board of Internal Medicine (1992) and American Board of Nephrology and Hypertension (1996) and was elected Fellow of the American College of Physicians in 1999. Specialist Degree in Internal Medicine and of Nephrology in 1996 and the Degree in Clinical Pharmacology in 2008 given by the "Ordem dos Médicos" of Portugal (Portuguese Medical Association). Participated in several clinical studies including the EVOLVE Trial. Published approximately 40 articles, reviews and book chapters (in English, Portuguese and French). Participated in numerous conferences in Portugal, USA, Brazil, Asia and Africa, including CMEs organized by ISN Global Outreach (in Angola, Mozambique, Zambia and Democratic Republic of Congo). Actively involved in the "Sociedade Portuguesa de Nefrologia" and the "Sociedade Portuguesa de Transplante". Currently works at the Renal Transplant Unit of the Hospital Santa Cruz and is Assistant Professor of Pharmacology at the University of Lisbon. He directs the dialysis unit Eurodial Obidos/Gaeiras, with 170 patients, all on online HDF. Currently involved in studies of pulse wave velocitiy in patients undergoing HDF as well as new approaches to anemia management.
DaVita believes that strong, quality leadership can improve the lives of patients by facilitating better patient care. Medical directors can stimulate superior clinical outcomes through effective leadership and higher standards. In Portugal, DaVita physicians work with a highly-skilled team of nephrologists who obtained significant dialysis and clinical nephrology experience in many of Portugal‘s leading clinical centers.
Locate a center near you.Search Now
Leading the charge in clinical research, innovation and operations.Learn More
Get to know some of the world's leading nephrologists who are building DaVita's patient care programs.Meet the Team
Take the first step in understanding kidney disease and the right treatment for you.Find Treatments
We are humbled and motivated by the recognition we receive for patient care, clinical and business innovation and corporate citizenship.View Awards